Last reviewed · How we verify
Continuous DOAC therapy
Continuous DOAC therapy maintains uninterrupted anticoagulation using direct oral anticoagulants without treatment gaps.
Continuous DOAC therapy maintains uninterrupted anticoagulation using direct oral anticoagulants without treatment gaps. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment, Acute coronary syndrome.
At a glance
| Generic name | Continuous DOAC therapy |
|---|---|
| Also known as | Oral Anticoagulation therapy |
| Sponsor | Johns Hopkins University |
| Drug class | Direct oral anticoagulant (DOAC) |
| Target | Factor Xa or Factor IIa (thrombin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Direct oral anticoagulants (DOACs) work by inhibiting specific clotting factors (typically Factor Xa or thrombin/Factor IIa) to prevent thrombus formation. Continuous therapy refers to an uninterrupted dosing regimen without scheduled breaks, which may improve efficacy and reduce thrombotic events compared to interrupted dosing patterns in certain clinical scenarios.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism prevention and treatment
- Acute coronary syndrome
Common side effects
- Bleeding (major and minor)
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Dyspepsia
Key clinical trials
- The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation (PHASE3)
- A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (PHASE2)
- DOAC - Dosing Options in AntiCoagulation Prophylaxis (PHASE3)
- RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing (PHASE3)
- Short-term Interruption Versus Continuous Anticoagulation in Colorectal Polypectomy (PHASE4)
- Effect of Oral Antiplatelet or Anticoagulant Drugs on Postoperative Bleeding Risk and Venous Closure Rate in Patients With Lower Extremity Varicose Veins After Radiofrequency Ablation
- inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT (PHASE4)
- The Nordic Aortic Valve Intervention Trial 4 (NOTION-4) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |